Literature DB >> 21501130

A comparison of low vs conventional-dose heparin for minimal cardiopulmonary bypass in coronary artery bypass grafting surgery.

Y Fromes1, K Daghildjian, L Caumartin, M Fischer, I Rouquette, P Deleuze, O M Bical.   

Abstract

The biocompatibility of minimal extracorporeal circuits has improved; however, anticoagulation is still required. We compared standard high-dose anticoagulation with a low-dose heparin regimen in a retrospective study of patients who underwent coronary bypass surgery using minimal cardiopulmonary bypass. One hundred patients who received 300 IU.kg(-1) heparin were compared with 68 patients who received heparin according to an individually adjusted activated coagulation time target of 300 s, resulting in a mean (SD) heparin dose of 145 (30) IU.kg(-1) . There were no thromboembolic events in either group; however, patients in the low-dose group had lower 24-hour mean (SD) postoperative blood loss than the conventional group (545 (61) vs 680 (88) ml, p=0.001) and a reduced rate of transfusion of allogeneic blood (15% patients transfused vs 32%, p=0.01). An individually tailored low-dose heparin regimen for minimal cardiopulmonary bypass is safe and may be associated with reduced bleeding and lower transfusion requirements.
© 2011 The Authors. Anaesthesia © 2011 The Association of Anaesthetists of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21501130     DOI: 10.1111/j.1365-2044.2011.06709.x

Source DB:  PubMed          Journal:  Anaesthesia        ISSN: 0003-2409            Impact factor:   6.955


  7 in total

Review 1.  Use of minimal invasive extracorporeal circulation in cardiac surgery: principles, definitions and potential benefits. A position paper from the Minimal invasive Extra-Corporeal Technologies international Society (MiECTiS).

Authors:  Kyriakos Anastasiadis; John Murkin; Polychronis Antonitsis; Adrian Bauer; Marco Ranucci; Erich Gygax; Jan Schaarschmidt; Yves Fromes; Alois Philipp; Balthasar Eberle; Prakash Punjabi; Helena Argiriadou; Alexander Kadner; Hansjoerg Jenni; Guenter Albrecht; Wim van Boven; Andreas Liebold; Fillip de Somer; Harald Hausmann; Apostolos Deliopoulos; Aschraf El-Essawi; Valerio Mazzei; Fausto Biancari; Adam Fernandez; Patrick Weerwind; Thomas Puehler; Cyril Serrick; Frans Waanders; Serdar Gunaydin; Sunil Ohri; Jan Gummert; Gianni Angelini; Volkmar Falk; Thierry Carrel
Journal:  Interact Cardiovasc Thorac Surg       Date:  2016-01-26

2.  Accuracy of point-of-care coagulation testing during cardiopulmonary bypass in a patient post COVID-19 infection.

Authors:  Nimrat Grewal; David Yousef; Meindert Palmen; Robert Klautz; Jeroen Eikenboom; Jeroen Wink
Journal:  J Cardiothorac Surg       Date:  2022-05-07       Impact factor: 1.522

3.  Heparin dose and postoperative bleeding in patients undergoing cardiopulmonary bypass.

Authors:  Mark W Rosin; David Holt
Journal:  J Extra Corpor Technol       Date:  2013-12

4.  Heparin dose calculated according to lean body weight during on-pump heart surgery.

Authors:  Aslıhan Aykut; Ülkü Sabuncu; Zeliha Aslı Demir; Eda Balcı; Başak Soran Türkcan; Utku Ünal; Ayşegül Özgök
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2018-09-16       Impact factor: 0.332

5.  Less is more: We are administering too much protamine in cardiac surgery.

Authors:  Francesco De Simone; Pasquale Nardelli; Margherita Licheri; Giovanna Frau; Martina Baiardo Redaelli; Fabrizio Monaco; Alberto Zangrillo; Giovanni Landoni
Journal:  Ann Card Anaesth       Date:  2021 Apr-Jun

Review 6.  Mechanisms of oxidative stress and myocardial protection during open-heart surgery.

Authors:  Nikolaos G Baikoussis; Nikolaos A Papakonstantinou; Chrysoula Verra; Georgios Kakouris; Maria Chounti; Panagiotis Hountis; Panagiotis Dedeilias; Michalis Argiriou
Journal:  Ann Card Anaesth       Date:  2015 Oct-Dec

7.  Expression profile analysis based on DNA microarray for patients undergoing off-pump coronary artery bypass surgery.

Authors:  Yunpeng Sun; Yongsheng Gao; Jingnan Sun; Xuguang Liu; Dashi Ma; Chunye Ma; Yong Wang
Journal:  Exp Ther Med       Date:  2016-01-18       Impact factor: 2.447

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.